 |
Roche's Actemra faces further delay in US for RA
Friday 5 December 2008
The US approval of Roche's novel biological rheumatoid arthritis drug Actemra (tocilizumab) has been further delayed after the FDA requested that Roche submit a risk evaluation and mitigation strategy (REMS) plan as well as additional preclinical studies.
Latest News
Pancreatic enzyme products should warn of pig virus risks, US panel says
Labelling for Solvay's Creon (pancrelipase delayed-release) and other pancreatic enzyme products (PEPs) that are approved as drugs should warn about the potential human risks from swine viruses, a US FDA advisory panel unanimously recommended on December 2nd.
Thursday 4 December 2008
Philippines implements new cheaper medicines law
The Philippines has now finalised the implementing rules and regulations for the cheaper medicines legislation it passed earlier this year after lengthy debate. The rules clarify how the new law should be applied in practice and there is no change to its basic provisions.
Thursday 4 December 2008
Evotec collaborates with Novartis on drug discovery
Evotec is to receive more than $28 million through a drug discovery collaboration with Novartis for novel small molecule therapies. Under the three-year deal, Evotec will develop the molecules up to preclinical development and then Novartis will take them through clinical development to commercialisation.
Thursday 4 December 2008
High prices restrict access to drugs in low-income countries
The availability of essential medicines for public healthcare in low-income countries is very limited and patients have to buy drugs in the private sector at far higher prices, despite such countries'pharma spending accounting for 20–60% of healthcare budgets.
Thursday 4 December 2008
More News
Most Read
- Roche snaps up more biotech firms
- Omeros appoints David Mann to Board
- Yondelis to be filed for ovarian cancer after Phase III success
- Amgen's denosumab succeeds in key osteoporosis trial
- Elan and Wyeth's Alzheimer's hope fails to impress
- BMS makes $4.5 billion bid for ImClone Systems
- Xarelto gets EU CHMP nod
Features & Analysis
Editorial: Shaking the antitrust stick
The European Commission has finally presented its preliminary report on why competition is not working as it should in the EU pharmaceutical sector. Is it an indictment of widespread anticompetitive activity by originator companies, or simply a compendium of figures and selective quotations that fails to address the real issues affecting access to medicines?
Editorial - December 2008
Scrip Pharma and Biotech Stock Tracker - October 2008
In Scrip's Stock Tracker for October, US reporter Christopher Spillane reviews the impact of recent political intervention and global turmoil on both the capital markets in general and the 15 biopharmaceuticals stocks followed in this monthly feature.
Stock Tracker - October 2008
What Obama's victory means for pharma
The new US President will push to get more Americans covered by health insurance, which should mean more unit sales of pharmaceuticals. But he also will attack drug pricing, so that higher volume may not equal higher profits, reports Daniel B Moskowitz
Market Insight - 21 November 2008
EU experts assess the role of biocides in antibiotic resistance
Could washing the dishes or applying make-up be contributing to the rise in antibiotic resistance? This is the worrying prospect raised by an advisory committee to the European Commission...
Ian Schofield - 14 November 2008
More Analysis
Blog
MicroRNA – a technology to rival RNAi?
One of the hot topics in drug discovery at the moment is microRNA (miRNA). MicroRNAs are short pieces of single-stranded RNA, about 21-23 bases long, that bind to matching sequences of messenger RNA, thereby rendering them double-stranded and inhibiting the production of the corresponding protein.
Read More
Posted 01/12/2008 15:43:18 PM
by Dr Peter Charlish,
Analyst
Sir Alan Sugar's firm targets messages to doctors' waiting rooms
Doctors waiting rooms full of nervous patients are soulless places, but their mood may soon be lightened in the UK by digital screens displaying health messages from Amscreen Healthcare, a new digital signage company from the well-known serial UK entrepreneur and TV personality, Sir Alan Sugar.
Read More
Posted 01/12/2008 10:55:31 AM
by John Davis,
Managing Editor
About Scrip
Scrip World Pharmaceutical News provides you with high quality news coverage of pharma and biotech and also gives you strategic data and analysis.
Benefits include:
›› Daily email headlines
›› Searchable news
archive
›› Weekly copies of Scrip
›› Bespoke Scrip supplements
›› Plus the Scrip Yearbook
and Scrip League Tables
Events
2nd Annual Vaccines Asia 2008
10 November 2008
Renaissance Beijing Capital Hotel,
China
AAPS Annual Meeting & Exposition
16 November 2008
Atlanta,
USA
Scrip Directory
Scrip Directory 2008
Search over 20,000 international contacts and access potential business opportunities
© Informa plc. All rights reserved. This site is owned and operated by Informa plc ("Informa") whose registered office is
Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
